maestro axis software version 2.4.2 Search Results


90
PANalytical axios advanced x-ray fluorescence (xrf) spectrometer
Axios Advanced X Ray Fluorescence (Xrf) Spectrometer, supplied by PANalytical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/maestro+axis+software+version+2%2E4%2E2/axios+x+ray+fluorescence+spectrometer/10__1016_slash_j__palaeo__2019__109423-108-22-21
Average 90 stars, based on 1 article reviews
axios advanced x-ray fluorescence (xrf) spectrometer - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Axion BioSystems axion integrated studio (axis) 2.4.2 software
Axion Integrated Studio (Axis) 2.4.2 Software, supplied by Axion BioSystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/maestro+axis+software+version+2%2E4%2E2/axion+integrated+studio+software/pmc11275104-92-24-20
Average 90 stars, based on 1 article reviews
axion integrated studio (axis) 2.4.2 software - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Axion BioSystems axis software version 2.4.2
Axis Software Version 2.4.2, supplied by Axion BioSystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/maestro+axis+software+version+2%2E4%2E2/axis+software+version+2+4+2/pmc07647070-182-7-11
Average 90 stars, based on 1 article reviews
axis software version 2.4.2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Axion BioSystems maestro axis software version 2.4.2
Maestro Axis Software Version 2.4.2, supplied by Axion BioSystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/maestro+axis+software+version+2%2E4%2E2/maestro+axis+software/pm30355486-210-176-182
Average 90 stars, based on 1 article reviews
maestro axis software version 2.4.2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Axion BioSystems 5 μm nitrosynapsin treatment
a Spontaneous action potentials (sAP) at resting membrane potential (RMP). WT/WT hiPSC-derived cerebrocortical neuron data in black, M146V/WT and APP swe /WT in red. b Quantification of sAP frequency. c Representative traces of glutamate-evoked currents from neurons voltage-clamped at −70 mV. d Glutamate-evoked current density. e , f Inhibition by 5–10 μM memantine or <t>NitroSynapsin.</t> Representative traces of WT/WT, M146V/WT and APP swe /WT neurons clamped at −70 mV (e). Percent inhibition by memantine (Mem) or NitroSynapsin (NitroSyn) in M146V/WT and APP swe /WT neurons vs. their respective WT/WT isogenic controls (f). Sample size represents total number of neurons recorded and is listed above bars. Data are mean ± SEM. Exact p values are listed above bars in this and subsequent figures unless otherwise specified. Statistical significance analyzed by ANOVA with post hoc Dunnett’s test.
5 μm Nitrosynapsin Treatment, supplied by Axion BioSystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/maestro+axis+software+version+2%2E4%2E2/5+%CE%BCm+nitrosynapsin+treatment/pmc07704704-97-31-33
Average 90 stars, based on 1 article reviews
5 μm nitrosynapsin treatment - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

N/A
The Recombinant Human CCL26 Eotaxin 3 aa 24 94 Protein from R D Systems is derived from E coli The Recombinant Human CCL26 Eotaxin 3 aa 24 94 Protein has been validated for the following
  Buy from Supplier

N/A
Rabbit polyclonal antibody to Ataxin 3 Isotype Note: IgG Host Note: Rabbit Conjugation Note: Unconjugated Reactivity Note: Human, Mouse, Rat Application Note: WB, IHC-P, P-ELISA
  Buy from Supplier


N/A
The Ataxin 1 Antibody (S76-8) [Alexa Fluor® 405] from Novus is a Ataxin 1 antibody to Ataxin 1. This antibody reacts with Human, Mouse, Rat. The Ataxin 1 antibody has been validated for the following
  Buy from Supplier

N/A
The Axin-1 Antibody [DyLight 550] from Novus is a Axin-1 antibody to Axin-1. This antibody reacts with Mouse. The Axin-1 antibody has been validated for the following applications: Western Blot.
  Buy from Supplier

N/A
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a
  Buy from Supplier

Image Search Results


a Spontaneous action potentials (sAP) at resting membrane potential (RMP). WT/WT hiPSC-derived cerebrocortical neuron data in black, M146V/WT and APP swe /WT in red. b Quantification of sAP frequency. c Representative traces of glutamate-evoked currents from neurons voltage-clamped at −70 mV. d Glutamate-evoked current density. e , f Inhibition by 5–10 μM memantine or NitroSynapsin. Representative traces of WT/WT, M146V/WT and APP swe /WT neurons clamped at −70 mV (e). Percent inhibition by memantine (Mem) or NitroSynapsin (NitroSyn) in M146V/WT and APP swe /WT neurons vs. their respective WT/WT isogenic controls (f). Sample size represents total number of neurons recorded and is listed above bars. Data are mean ± SEM. Exact p values are listed above bars in this and subsequent figures unless otherwise specified. Statistical significance analyzed by ANOVA with post hoc Dunnett’s test.

Journal: Molecular psychiatry

Article Title: NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models

doi: 10.1038/s41380-020-0776-7

Figure Lengend Snippet: a Spontaneous action potentials (sAP) at resting membrane potential (RMP). WT/WT hiPSC-derived cerebrocortical neuron data in black, M146V/WT and APP swe /WT in red. b Quantification of sAP frequency. c Representative traces of glutamate-evoked currents from neurons voltage-clamped at −70 mV. d Glutamate-evoked current density. e , f Inhibition by 5–10 μM memantine or NitroSynapsin. Representative traces of WT/WT, M146V/WT and APP swe /WT neurons clamped at −70 mV (e). Percent inhibition by memantine (Mem) or NitroSynapsin (NitroSyn) in M146V/WT and APP swe /WT neurons vs. their respective WT/WT isogenic controls (f). Sample size represents total number of neurons recorded and is listed above bars. Data are mean ± SEM. Exact p values are listed above bars in this and subsequent figures unless otherwise specified. Statistical significance analyzed by ANOVA with post hoc Dunnett’s test.

Article Snippet: Recordings were performed in BrainPhys medium at 37 °C using the ‘neural spikes analog mode’ setting with a sampling frequency of 12.5 kHz at baseline (prior to) and after 5 μM NitroSynapsin treatment (Axion Biosystems Maestro Axis Software version 2.4.2) on a Maestro MEA (Axion Biosystems).

Techniques: Derivative Assay, Inhibition

WT/WT hiPSC-derived cerebrocortical neuron data in black, M146V/WT and APP swe /WT in red. a Representative calcium imaging traces showing decrease in [Ca 2+ ] i and transients after application of 5 μM NitroSynapsin. Dotted line represents decrease in [Ca 2+ ] i . b Quantification of difference in normalized fluorescence (ΔF/F 0Drug - ΔF/F 0Control ) in response to 5 μM memantine (Mem) or equimolar NitroSynapsin (NitroSyn). c Quantification of calcium event frequency before and after application of 5 μM NitroSynapsin. d Fluo-4 images of WT/WT and ΔE9/WT cultures showing [Ca 2+ ] i before (control) and after application of NitroSynapsin (5 μM NitroSyn). Scale bar: 10 μm. e Quantification of difference in normalized fluorescence (ΔF/F 0Drug - ΔF/F 0Control ) in response to 5 μM memantine (Mem) or equimolar NitroSynapsin (NitroSyn). f Noise-floor normalized power spectrum showing concentration of power in low frequencies (<1 Hz) and at 6 Hz (theta oscillation). WT in black; AD in red. g Quantification of mean log power (0.2–1 Hz) in WT and AD cultures. h Quantification of mean log power difference (0.2–1 Hz) after treatment with 5 μM NitroSynapsin in WT and AD cultures (post - pre). Data are mean ± SEM. Statistical significance analyzed by two-tailed unpaired Student’s t-test (*) in b, e, g and h; by ANOVA with post hoc Dunnett’s test (*) for multiple comparisons to WT; and by Sidak’s test (#) corrected for multiple comparisons between selected pairs in c.

Journal: Molecular psychiatry

Article Title: NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models

doi: 10.1038/s41380-020-0776-7

Figure Lengend Snippet: WT/WT hiPSC-derived cerebrocortical neuron data in black, M146V/WT and APP swe /WT in red. a Representative calcium imaging traces showing decrease in [Ca 2+ ] i and transients after application of 5 μM NitroSynapsin. Dotted line represents decrease in [Ca 2+ ] i . b Quantification of difference in normalized fluorescence (ΔF/F 0Drug - ΔF/F 0Control ) in response to 5 μM memantine (Mem) or equimolar NitroSynapsin (NitroSyn). c Quantification of calcium event frequency before and after application of 5 μM NitroSynapsin. d Fluo-4 images of WT/WT and ΔE9/WT cultures showing [Ca 2+ ] i before (control) and after application of NitroSynapsin (5 μM NitroSyn). Scale bar: 10 μm. e Quantification of difference in normalized fluorescence (ΔF/F 0Drug - ΔF/F 0Control ) in response to 5 μM memantine (Mem) or equimolar NitroSynapsin (NitroSyn). f Noise-floor normalized power spectrum showing concentration of power in low frequencies (<1 Hz) and at 6 Hz (theta oscillation). WT in black; AD in red. g Quantification of mean log power (0.2–1 Hz) in WT and AD cultures. h Quantification of mean log power difference (0.2–1 Hz) after treatment with 5 μM NitroSynapsin in WT and AD cultures (post - pre). Data are mean ± SEM. Statistical significance analyzed by two-tailed unpaired Student’s t-test (*) in b, e, g and h; by ANOVA with post hoc Dunnett’s test (*) for multiple comparisons to WT; and by Sidak’s test (#) corrected for multiple comparisons between selected pairs in c.

Article Snippet: Recordings were performed in BrainPhys medium at 37 °C using the ‘neural spikes analog mode’ setting with a sampling frequency of 12.5 kHz at baseline (prior to) and after 5 μM NitroSynapsin treatment (Axion Biosystems Maestro Axis Software version 2.4.2) on a Maestro MEA (Axion Biosystems).

Techniques: Derivative Assay, Imaging, Fluorescence, Concentration Assay, Two Tailed Test

a-c Representative heat maps and raster plots of MEA recordings in WT/WT (a), M146V/WT (b), and APP swe /WT (c) cultures before ( left ) and after ( center and right ) treatment with 5 and 10 μM NitroSynapsin, respectively. Red boxes represent examples of network bursts. d-f Quantification of MEA recordings. Mean firing rate (d). Network burst frequency quantification (e). Quantification of synchrony index (f). Data are mean ± SEM. Sample size listed above bar graphs (*, # p < 0.05; **, ## p < 0.01; ***, ### p < 0.001; #### p < 0.0001 by ANOVA with post-hoc Dunnett’s test (*) for multiple comparisons to WT and Sidak’s test ( # ) corrected for multiple comparisons between selected pairs).

Journal: Molecular psychiatry

Article Title: NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models

doi: 10.1038/s41380-020-0776-7

Figure Lengend Snippet: a-c Representative heat maps and raster plots of MEA recordings in WT/WT (a), M146V/WT (b), and APP swe /WT (c) cultures before ( left ) and after ( center and right ) treatment with 5 and 10 μM NitroSynapsin, respectively. Red boxes represent examples of network bursts. d-f Quantification of MEA recordings. Mean firing rate (d). Network burst frequency quantification (e). Quantification of synchrony index (f). Data are mean ± SEM. Sample size listed above bar graphs (*, # p < 0.05; **, ## p < 0.01; ***, ### p < 0.001; #### p < 0.0001 by ANOVA with post-hoc Dunnett’s test (*) for multiple comparisons to WT and Sidak’s test ( # ) corrected for multiple comparisons between selected pairs).

Article Snippet: Recordings were performed in BrainPhys medium at 37 °C using the ‘neural spikes analog mode’ setting with a sampling frequency of 12.5 kHz at baseline (prior to) and after 5 μM NitroSynapsin treatment (Axion Biosystems Maestro Axis Software version 2.4.2) on a Maestro MEA (Axion Biosystems).

Techniques:

a Representative images of 2-month old WT/WT, M146V/WT, and APP swe /WT organoids stained for Nestin, TBR2, and CTIP2 showing cortical layers. b Representative raster plots of MEA recordings in 3-month old WT/WT, M146V/WT, and APP swe /WT organoids before (left) and after treatment with 10 μM memantine (center) or 10 μM NitroSynapsin (right). Red boxes represent examples of network bursts. c - f Quantification of MEA recordings. Mean firing rate; percentage inhibition with 10 μM memantine or NitroSynapsin; network burst frequency, and synchrony index. Data are mean ± SEM. Sample size listed in the bar graphs (*, # p < 0.05; **, ## p < 0.01 by ANOVA with post-hoc Dunnett’s test (*) for multiple comparisons to WT and Sidak’s test ( # ) corrected for multiple comparisons between selected pairs).

Journal: Molecular psychiatry

Article Title: NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models

doi: 10.1038/s41380-020-0776-7

Figure Lengend Snippet: a Representative images of 2-month old WT/WT, M146V/WT, and APP swe /WT organoids stained for Nestin, TBR2, and CTIP2 showing cortical layers. b Representative raster plots of MEA recordings in 3-month old WT/WT, M146V/WT, and APP swe /WT organoids before (left) and after treatment with 10 μM memantine (center) or 10 μM NitroSynapsin (right). Red boxes represent examples of network bursts. c - f Quantification of MEA recordings. Mean firing rate; percentage inhibition with 10 μM memantine or NitroSynapsin; network burst frequency, and synchrony index. Data are mean ± SEM. Sample size listed in the bar graphs (*, # p < 0.05; **, ## p < 0.01 by ANOVA with post-hoc Dunnett’s test (*) for multiple comparisons to WT and Sidak’s test ( # ) corrected for multiple comparisons between selected pairs).

Article Snippet: Recordings were performed in BrainPhys medium at 37 °C using the ‘neural spikes analog mode’ setting with a sampling frequency of 12.5 kHz at baseline (prior to) and after 5 μM NitroSynapsin treatment (Axion Biosystems Maestro Axis Software version 2.4.2) on a Maestro MEA (Axion Biosystems).

Techniques: Staining, Inhibition